CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 89 enrolled
Drug / intervention
CF101 +1 moredrug
Likely dose
CF101 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01033422
NCT01033422Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Can-Fite BioPharma·interventional·Posted Dec 16, 2009·Updated May 12, 2022

In Brief

A Phase 2 clinical trial evaluating CF101 and Placebo for for Ocular Hypertension and Glaucoma. Completed, enrolled 89 participants across 3 sites in 2 countries.

Detailed Summary

This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma. Eligible patients with elevated intraocular pressure will be evaluated and treated by ophthalmologist investigators, and will receive either CF101 pills or placebo (dummy) pills twice daily for 16 weeks. Ocular pressure, visual fields, and other aspects of safety and effectiveness will be monitored on a regular basis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Glaucoma
CountriesBulgaria, Israel
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 16, 2009
Enrollment StartOct 1, 2010
Primary CompletionDec 1, 2016
Study CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 16.5 years ago

Interventions

CF101drug

CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks

Placebo fordrug

Matching placebo tablets orally every 12 hours for 16 weeks